Bpifrance supplied funding through three separate units to help take Satt Conectus-allied rare disease drug developer Dynacure's latest round to $55m.

Dynacure, a France-based drug developer spun out of Institute of Genetic and Molecular and Cellular Biology (IGBMC) in Strasbourg, today completed a €50m ($55m) series C round backed by government-owned investment bank Bpifrance.
Bpifrance invested through its Large Venture, Fabs and Fonds Biothérapies Innovantes et Maladies Rares funds. The round was led by investment firm Perceptive Advisors.
The deal was rounded off by Andera Partners, Kurma Partners, Pontifax and unnamed funds managed by Tekla Capital Management. IGBMC is…